Baxalta

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in package.lua at line 80: module 'strict' not found.

Baxalta
Traded as NYSE: BXLT[1]
Industry Biotechnology
Founded 2015
Spun off from Baxter International
Key people
 Ludwig N. Hantson, Ph.D
(CEO & President)
Robert J. Hombach.
(CFO) & (COO)
Products Hematology, Immunology, Pulmonology
Number of employees
 16,000[2]
Website www.baxalta.com

Baxalta (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound'[3]) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.[2][4] with revenue of $6 billion.

Company History

Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol for $225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for $900 million.[2][5]

In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company[6][7] sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3.[8] This deal would also be set to create the largest global biotech company focused solely on rare diseases.[8] In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.[9] Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.[10]

Pipeline

Hematology
  • BAX 855 – long-acting pegylated full-length rFVIII[11] hemophilia A drug awaiting FDA approval in conjunction with Nektar Therapeutics.[12] It is also undergoing Phase II trials for sickle cell.[13]
  • BAX 111 – submitted as a recombinant von Willebrand factor treatment for von Willebrand disease, filed with the FDA in December 2014.[14] In August 2015, data was released and published in the journal Blood,[15] which indicated that 100 percent of the patients treated with BAX 111 were successful in the management of bleeding episodes.[16][17]
  • BAX 817 – Recombinant factor VIIa[13]
  • BAX 335 – FIX gene therapy in Phase II.[13]
  • BAX 930 – Recombinant ADAMTS13[13]
  • BAX 826 – Recombinant, extended half-life Factor VIII[13]
  • BAX 888 – Factor VIII gene therapy in Phase I trials.[13]
Immunology
Oncology
  • MM-398 – Co-developed with Merrimack Pharmaceuticals.[18] Undergoing EU reviews for post-Gemcitabine pancreatic cancer, in Phase III trials for gastric cancer[13] Currently undergoing priority review with the FDA[19] for a new drug application.[20][21]
  • Pacritinib – Phase III trials for Myelofibrosis, Phase I trials for Acute Myeloid Leukemia and pre-clinical for Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome and Polycythemia Vera.[13]
  • Rigosertib – Phase III trials for Myelodysplastic Syndrome.[13]
  • BAX 069 – also known as Imalumab, in Phase II trials for Malignant Ascites and Metastatic Colorectal cancer.[13]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ 8.0 8.1 Lua error in package.lua at line 80: module 'strict' not found.
  9. ↑ http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/
  10. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  11. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  12. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  13. ↑ 13.00 13.01 13.02 13.03 13.04 13.05 13.06 13.07 13.08 13.09 13.10 13.11 13.12 13.13 13.14 13.15 Lua error in package.lua at line 80: module 'strict' not found.
  14. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  15. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  16. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  17. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  18. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  19. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  20. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  21. ↑ Lua error in package.lua at line 80: module 'strict' not found.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Baxalta&oldid=722432025"